To: Administrative Officers, Deans, Department Chairs, Directors, UCLA Health, Vice Chancellors, and Vice Provosts
The Office of the Vice Chancellor for Research and Creative Activities has updated UCLA Policy 992: Use of Biohazardous Materials and Recombinant or Synthetic Nucleic Acid Molecules in Research and Teaching Activities.
In 2020, the Institutional Biosafety Committee (IBC) modified their oversight regarding clinical research activities that did not include materials covered by the National Institute of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. Previously, the IBC sought to review/approve these activities, but considering the role of Health System infection control, their review was ultimately determined to be redundant. Policy 992 has been updated to reflect this change.
In accordance with UCLA Policy 100: Administrative Policies & Procedures, this updated policy has been placed on the Administrative Policies and Procedures website for a 30-day public review and comment period. Please encourage faculty and staff in your departments to review the updated policy and submit comments via the webpage by June 6, 2022.
Should you have any questions about the policy process, please contact Anna Joyce at firstname.lastname@example.org. Thank you for taking the time to review the policies and provide feedback.
Roger M. Wakimoto
Vice Chancellor for Research and Creative Activities